Our passion for innovation

Ncardia believes that stem cell technology fast-tracks the delivery of better medicines to patients by improving the drug discovery process. We develop, produce and commercialize highly-predictive human cellular (disease) assay systems for safety and efficacy testing aiming to accelerate and improve drug candidate selection, reduce costs and ultimately increase drug discovery and development efficiency.


hiPSC-derived Cardiac and Neural products

The cardiac product portfolio includes hiPSC-derived cardiomyocytes, frozen or in ready-to-use CardioPlateTM assay plates. The neural cell product portfolio contains the pan-neuronal cells CNS.4U®, peripheral neurons Peri.4U®, and astrocytes Astro.4U®.


Industry-leading iPSC Services

Ncardia provides its customers with a broad portfolio of cardiovascular iPSC services for safety and efficacy testing and analysis. The safety services are pre-configured service packages based on electrophysiology, biochemistry and contraction assay technology for predictive safety pharmacology and toxicology testing. Efficacy services range from disease modeling to cardiovascular drug efficacy screening.


We are ready to help

Ncardia is committed to delivering to its clients working assay solutions, through in-house assay development and customized support. By combining our deep portfolio of differentiated cardiac and neuronal iPSC cell products with our well-equipped laboratories, we provide scientists with top quality support for almost every application. The company has freely available application scientists knowledgeable in areas including but not limited to electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology and toxicology testing. Do not hesitate to talk to our experts today!